retatrutide cons Promises Big Weight Loss, but Safety Remains a Question 28.7% Weight Loss in New

About 1 in 8 adults in the United States has used a GLP-1 drug like Ozempic or Mounjaro at some point in their life, and half of them about 6% of adults, or more than 15 million people are currently using a prescription, according to new survey data from KFF

Aranas, C

In fact, the 2026 NFP U.S

The weight loss results in clinical trials are genuinely impressive

A New Era in Peptide-Based Weight Loss In the ever-evolving world of metabolic science, Retatrutide is emerging as one of the most powerful multi-pathway peptides to date

The platform cannot guarantee that any individual will receive a prescription, as that determination rests entirely with the evaluating clinician